GlassScriptPhysician profile
Lara Blumberg
NPI 1174532477
$3,791.58
in general payments reported to CMS, 2019-2025
35 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,501 · 2020: $372 · 2021: $170 · 2022: $84.13 · 2023: $564 · 2024: $626 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.38 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $465.34 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $367.37 | 2019-2025 | |
| Lilly USA, LLC | $285.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $198.07 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $190.83 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $167.66 | 2019-2024 | |
| Astellas Pharma US INC | $159.07 | 2024-2025 | Veozah |
| Amgen INC. | $135.79 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Allergan, INC. | $135.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.49 | 2019 | |
| Amarin Pharma, INC. | $98.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.24 | 2019-2020 | |
| Abbott Laboratories | $76.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.08 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $67.36 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $65.93 | 2019-2025 | Trintellix |
| Nevro Corp. | $57.17 | 2023-2024 | Senza |
| Janssen Pharmaceuticals, INC | $49.03 | 2019-2020 | |
| Shire North American Group INC | $45.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $44.41 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.38 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.18 | 2024-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $32.34 | 2020 | |
| Almatica Pharma LLC | $29.05 | 2024 | Teriparatide, Loreev Xr |
| Jazz Pharmaceuticals INC. | $28.29 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.73 | 2020-2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $23.64 | 2025 | Rexulti |
| Corium, LLC | $22.49 | 2023 | Azstarys |
| Lundbeck LLC | $19.38 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $17.15 | 2024 | |
| Currax Pharmaceuticals LLC | $16.84 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $16.40 | 2024 | |
| Dexcom, INC. | $16.10 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Blumberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.